Scarica l'app Stockscreener
33.05
4.45%
-1.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$34.59
Aprire:
$34.74
Volume 24 ore:
755.25K
Relative Volume:
2.08
Capitalizzazione di mercato:
$1.82B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
30.90
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
-15.49%
1M Prestazione:
-14.33%
6M Prestazione:
-4.73%
1 anno Prestazione:
+17.45%
Intervallo 1D:
$32.98
$34.87
Intervallo di 1 settimana:
$32.53
$39.99
Portata 52W:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
33.05 | 1.82B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
New York State Teachers Retirement System Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus plunges as mid-stage trial for depression therapy fails - MSN
Supernus' depression treatment fails mid-stage trial, shares plunge - MSN
Depression failure sends Supernus shares downwards - The Pharma Letter
How the (SUPN) price action is used to our Advantage - Stock Traders Daily
Supernus phase IIb results drag down the stock - BioWorld Online
Cantor Fitzgerald cuts Supernus stock rating, target to $36 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial - AOL
Supernus’s stock sinks after depression drug fails trial - Yahoo
Sanofi reaches consumer health deal; Supernus antidepressant fails study - BioPharma Dive
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & ... - The Bakersfield Californian
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; - GlobeNewswire
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsSUPN - ACCESS Newswire
Supernus stock falls after trial setback (update) (SUPN:NASDAQ) - Seeking Alpha
Supernus reports less than super data for depression drug - pharmaphorum
Supernus Plunges On Failed Phase 2b Study Of SPN-820 In Treatment-resistant Depression - Nasdaq
Supernus Pharma sinks after depression drug fails mid-stage trial goal - TradingView
Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint - Marketscreener.com
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression - GlobeNewswire
Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression - Marketscreener.com
Supernus' depression treatment fails mid-stage trial, shares plunge -February 18, 2025 at 04:49 pm EST - Marketscreener.com
Supernus' depression treatment fails mid-stage trial -February 18, 2025 at 04:35 pm EST - Marketscreener.com
Supernus Pharma stock tumbles after failed depression study By Investing.com - Investing.com Nigeria
Supernus Pharma stock tumbles after failed depression study - Investing.com India
Clinical Trial Setback: Supernus Depression Treatment Shows No Advantage Over Placebo - StockTitan
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57 - Marketscreener.com
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Yousif Capital Management LLC Sells 425 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLC - Defense World
Yousif Capital Management LLC Has $768,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Access to Parkinson’s medication likely by summer: Supernus official - Parkinson's News Today
Janney Montgomery Scott LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stephens Investment Management Group LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Q4 Earnings: CEO and CFO Set to Unveil Full Year Performance Metrics - StockTitan
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking - Simply Wall St
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells 9,477 Shares of Stock - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year HighHere's Why - MarketBeat
Supernus wins FDA approval for Parkinson’s pump on fourth try - MSN
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight - The Globe and Mail
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Stifel maintains hold on Supernus, price target at $38 - MSN
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Option Exercise |
29.61 |
2,573 |
76,187 |
12,722 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Option Exercise |
29.61 |
700 |
20,727 |
10,849 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 27 '25 |
Sale |
39.62 |
2,573 |
101,942 |
10,149 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Jan 28 '25 |
Sale |
39.62 |
700 |
27,734 |
10,149 |
3.23%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):